IRIXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends January 3
IRIDEX CORP
Financials through Q2 FY2026, quarter ended Jul 4, 2026Last filing: 10-Q on Aug 18, 2026
$0.77−0.04 (-5.48%)
Close on Oct 19, 2026
- Market cap
- $13.41M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
36.5%−6.3 pts over 5 years
Operating margin
-4.9%+13.2 pts over 5 years
Net margin
-8.4%+9.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +8.2% | -2.6% | +7.7% | +2.3% | |
| Gross profit | -1.4% | -8.8% | +4.3% | -0.4% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -32.2% | -31.6% | -126.4% | |
| Return on assets | -26.0% | -20.2% | -15.2% | |
| Current ratio | 5.62 | 2.92 | 1.91 | |
| Interest coverage | – | – | -44.3× | |
| Inventory turnover | 2.2× | 3.0× | 3.6× | |
| Capex to revenue | 2.3% | 0.3% | 0.3% | |
| Diluted shares | 10M | 14M | 17M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Iridex generated $33.88M from operations and spent $764.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$33.88M
Used
$764.00K
Capital expenditure$764.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-8.4%
×Asset turnover1.81×
×Equity multiplier8.30×
=Return on equity, FY2025-126.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -8.4% | 1.81× | 8.30× | -126.4% |
| FY2024 | -18.3% | 1.53× | 5.47× | -153.4% |
| FY2023 | -18.5% | 1.35× | 2.87× | -71.5% |
| FY2022 | -13.2% | 1.25× | 2.24× | -37.2% |
| FY2021 | -9.7% | 1.41× | 1.89× | -25.7% |
| FY2020 | -17.4% | 1.16× | 1.57× | -31.6% |
| FY2019 | -20.3% | 1.14× | 1.45× | -33.5% |
| FY2018 | -30.1% | 1.02× | 1.38× | -42.4% |
| FY2017 | -30.9% | 0.93× | 1.29× | -36.9% |
| FY2016 | -25.4% | 1.03× | 1.23× | -32.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$4.44M
- Cash generatingOperating cash flow above zero-$2.12M
- Return on assets improvedROA up on the prior year-25.9% → -15.2%
- Earnings backed by cashOperating cash flow above net income-$2.12M vs -$4.44M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.42 → 1.91
- No dilutionShare count did not rise16M → 17M
- Gross margin improvedGross margin up on the prior year40.07% → 36.50%
- More efficientAsset turnover rose1.41 → 1.81